Near-unicorn Prestige Biopharma eyes early-2021 IPO in South Korea
Singapore-based firm last valued at US$827m; does not say how much it is raising in IPO
Singapore
SINGAPORE-BASED Prestige Biopharma is in the midst of pursuing an initial public offering (IPO) on the Korea Exchange, with a targeted listing in early 2021, the firm's chief executive Lisa Park said in response to queries from The Business Times (BT).
Earlier on Friday, BT reported that Prestige Biopharma's Singapore-registered entity had been been fully acquired by the Korea Securities Depository (KSD), as shown in Dec 8 regulatory data on intelligence platform VentureCap Insights.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Far East Orchard acquires 49% stake in UK-based purpose-built student accommodation operator for £17.6 million
Nestle sales growth sputters on US slump, vitamin snags
BNP Paribas beats estimates as lower costs offset trading slump
TikTok ultimatum puts US firms in firing line for China response
Toyota and Nissan pair up with Tencent and Baidu for China AI arms race
BHP targets Anglo American in bid valuing miner at US$39 billion